Drug Trial Radar · NCT01762787
Phase I Methodology Study to Validate the Cantharidin Blister Model in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Jun 28, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Aug 17, 2010
Primary completion
Jan 14, 2011
Study completion Jan 14, 2011
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jan 8, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Single (participant)
- Primary purpose
- Other
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to refine the cantharidin-induced blister assay in healthy volunteers as a model of inflammatory disease. The study is an experimental trial in healthy volunteers in two parts; Part 1 to optimise the model and Part 2 to validate using two anti-inflammatory treatments with different modes of action.
Conditions
- Inflammation
Interventions
Cantharidin solutionDrug
5 microlitres of 0.025 to 0.5% topically on Day 1, 2 and 3
AspirinDrug
300mg three times daily orally over a course of 4 days (starting Day -3) Part 2 only
PrednisoloneDrug
30mg orally once a day over a course of 4 days (starting Day -3) Part 2 only
Placebo to aspirinDrug
0mg three times daily orally over a course of 4 days (starting Day -3) Part 2 only
Placebo to prednisoloneDrug
0mg orally once a day over a course of 4 days (starting Day -3) Part 2 only
Primary outcomes
What the sponsor says the trial is designed to measure.
- Blister volume of fluidTime frame: 48 hours
- Cell population in blister fluidTime frame: 48 hours
- Inflammatory mediators in blister fluidTime frame: 48 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Cambridge, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.